{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-26-000010","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2026-07-01T11:33:29+00:00","discovered_at":"2026-07-01T11:35:00.279338+00:00","generated_at":"2026-07-01T11:35:04.827451+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"iBio reports single-dose IBIO-610 achieves 98% Activin E inhibition at 4 weeks in obese NHP study","bullets":["Single dose of IBIO-610 reduced active Activin E by 98% at week 4 and 97% at week 8 vs baseline in obese NHPs.","When combined with semaglutide, IBIO-610 reduced lean mass loss by 73% versus semaglutide alone.","Data supports potential for infrequent dosing and fat-selective weight loss while preserving lean mass.","Full dataset to be presented at EASD Annual Meeting in Milan, September 28 – October 2, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-26-000010","json":"https://secwatch.observer/filing/0001420720-26-000010.json","markdown":"https://secwatch.observer/filing/0001420720-26-000010.md","text":"https://secwatch.observer/filing/0001420720-26-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072026000010/0001420720-26-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072026000010/ibio-20260701x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-01T11:35:04.827451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}